NEUP Stock Summary and Trading Ideas (Neuphoria Therapeutics | NASDAQ:NEUP)

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Neuphoria Therapeutics trades on the NASDAQ stock market under the symbol NEUP.

As of April 3, 2025, NEUP stock price declined to $5.66 with 20,138 million shares trading.

NEUP has a beta of 2.54, meaning it tends to be more sensitive to market movements. NEUP has a correlation of 0.10 to the broad based SPY ETF.

NEUP has a market cap of $9.94 million. This is considered a Sub-Micro Cap stock.

NEUP support price is $5.48 and resistance is $6.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEUP shares will trade within this expected range on the day.